OncoMatch/Clinical Trials/NCT04821778
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Is NCT04821778 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for esophagus cancer.
Treatment: Platinum based chemotherapy · Paclitaxel based chemotherapy · Immunotherapy · 5-FU Analog based chemotherapy · Nimotuzumab — Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer. A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients. Morerover, molecular targeting agents does not show clear efficacy in EC up to now. Nowadays, the pace of development of cancer immunotherapies is accelerating. Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy. There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy. The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage I, II, III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin ≥100g/L; Leukocytes ≥4,000 G/L; Neutrophil ≥2,000 G/L; Platelets ≥100,000/mm3
Kidney function
Creatinine: ≤1.5x ULN or CCR ≥60 ml/min
Liver function
AST/ALT: ≤2.5x ULN; Total bilirubin: ≤1.5x ULN
Normal organ and marrow function as defined below: Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify